General Information of Drug (ID: DMO3U4W)

Drug Name
VX-222 Drug Info
Synonyms
VX-222; Lomibuvir; 1026785-59-0; 1026785-55-6; VX 222; VX-222 (VCH-222, Lomibuvir); UNII-37L2LF4A2D; VCH222; VCH-222; VX222; 37L2LF4A2D; Lomibuvir (VX-222, VCH-222); 2-Thiophenecarboxylic acid, 5-(3,3-dimethyl-1-butyn-1-yl)-3-[(trans-4-hydroxycyclohexyl)[(trans-4-methylcyclohexyl)carbonyl]amino]-;2-Thiophenecarboxylic acid, 5-(3,3-dimethyl-1-butyn-1-yl)-3-[(trans-4-hydroxycyclohexyl)[(trans-4-methylcyclohexyl)carbonyl]amino]-
Indication
Disease Entry ICD 11 Status REF
Hepatitis C virus infection 1E51.1 Phase 2 [1]
Cross-matching ID
PubChem CID
24798764
ChEBI ID
CHEBI:94757
CAS Number
CAS 1026785-55-6
TTD Drug ID
DMO3U4W

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PSI-7977 DMLSUWZ HCV 1-6 infection 1E51 Approved [2]
Setrobuvir DMTNDM2 Hepatitis C virus infection 1E51.1 Phase 2 [3]
BI 207127 DMMSGAT Hepatitis C virus infection 1E51.1 Phase 2 [4]
Valopicitabine dihydrochloride DMFWZ2U Virus infection 1A24-1D9Z Phase 2 [5]
INX-189 DMSTJ6Q Hepatitis C virus infection 1E51.1 Phase 2 [6]
Tegobuvir DM6YI5T Hepatitis C virus infection 1E51.1 Phase 2 [7]
VX-759 DMJUSM8 Hepatitis C virus infection 1E51.1 Phase 2 [1]
VX-135 DMZ3FE8 Hepatitis C virus infection 1E51.1 Phase 2 [8]
BMS 791325 DMKH4PI Hepatitis C virus infection 1E51.1 Phase 2 [9]
Filibuvir DMNSYXB Hepatitis C virus infection 1E51.1 Phase 2 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B) TTMVBWH POLG_HCV1 Inhibitor [1]

References

1 2011 Pipeline of Vertex.
2 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
3 Clinical pipeline report, company report or official report of Anadys Pharmaceuticals (2011).
4 2011 Pipeline of Boehringer Ingelheim Pharma.
5 Valopicitabine dihydrochloride:a specific polymerase inhibitor of hepatitis C virus. Curr Opin Investig Drugs. 2007 Feb;8(2):150-8.
6 Clinical pipeline report, company report or official report of Bristol-Myers Squibb.
7 Clinical pipeline report, company report or official report of Gilead (2011).
8 All-oral HCV therapies near approval. Nat Rev Drug Discov. 2013 Jun;12(6):409-11.
9 2011 Pipeline of Bristol-Myers Squibb.
10 Clinical pipeline report, company report or official report of Pfizer (2011).